More clinically relevant animal models and greater analytical precision are needed to successfully advance sarcoma programs.
In this short lunchtime presentation, you’ll learn about the advantages of orthotopic vs. subcutaneous PDX models. Case studies will illustrate how individualized O-PDX models provide insight into acquired drug resistance and metastasis in their human counterparts.
Plus, you’ll learn about an opportunity screen drug candidates more quicky & cost-effectively by participating in an upcoming sarcoma CertiScreen. Class A sarcoma tumor models — all low passaged, highly characterized and annotated, US patient-consented, with extensive genomic data — from the Certis TumorBank, will be featured. Discover a better approach to — and a better partner for — preclinical development.